New drug duo tested in fight against advanced cervical cancer

NCT ID NCT06715241

Summary

This study is testing if adding a new drug called relatlimab to an existing immunotherapy (nivolumab) works better for locally advanced cervical cancer. About 77 patients will receive the two-drug combination or nivolumab alone for six weeks before starting standard chemoradiation. The main goal is to see if the combination causes tumors to shrink more often during this initial period.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHRU Besançon - Hôpital Jean Minjoz

    Besançon, 25030, France

  • CHRU Lille - Hôpital Jeanne de Flandre

    Lille, 59000, France

  • CHU STRASBOURG - Hôpital de Hautepierre

    Strasbourg, France

  • CHU Saint-Etienne - Pôle de Cancérologie

    Saint-Etienne, 42271, France

  • CHU de BREST - Hôpital Cavale Blanche

    Brest, 29200, France

  • CHU de Dijon

    Dijon, 21079, France

  • CHU de Limoges - Hôpital Dupuytren

    Limoges, 87042, France

  • CHU de Poitiers - Hôpital de la Milétrie

    Poitiers, 86021, France

  • Centre Antoine Lacassagne

    Nice, 06189, France

  • Centre CARIO - HPCA

    Plérin, 22190, France

  • Centre Eugène Marquis

    Rennes, 35042, France

  • Centre François Baclesse

    Caen, 14076, France

  • Centre Hospitalier Intercommunal de Créteil

    Créteil, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, France

  • Centre Jean Perrin

    Clermont-Ferrand, France

  • Centre Léon Bérard

    Lyon, 69373, France

  • Centre Oscar Lambret

    Lille, France

  • Groupe Hospitalier Diaconesses - Croix Saint-Simon

    Paris, 75012, France

  • Gustave Roussy

    Villejuif, 94805, France

  • ICANS - Institut de cancérologie Strasbourg Europe

    Strasbourg, 67200, France

  • ICL - Centre Alexis Vautrin

    Vandœuvre-lès-Nancy, 54519, France

  • ICO - Centre René Gauducheau

    Saint-Herblain, 44805, France

  • ICO Paul Papin

    Angers, 49055, France

  • Institut Bergonié

    Bordeaux, 33076, France

  • Institut Curie

    Paris, 75005, France

  • Institut Paoli Calmettes

    Marseille, 13273, France

  • Oncopole Claudius Regaud

    Toulouse, 31059, France

  • Recherche Oncologique Clinique 37 (ROC 37)

    Tours, 37170, France

  • Sainte-Catherine Institut du Cancer Avignon-Provence

    Avignon, 84918, France

  • Dijon, France

Conditions

Explore the condition pages connected to this study.